Background Smokers increasingly use e-cigarettes for many reasons, including attempts to quit combustible cigarettes and to use nicotine where smoking is prohibited. We aimed to assess the association between e-cigarette use and cigarette smoking cessation among adult cigarette smokers, irrespective of their motivation for using e-cigarettes.
Introduction
E-cigarettes (also known as electronic cigarettes, electronic nicotine delivery systems, vapour pens, and many other terms) are battery-powered devices that heat a solution of humectants (usually propylene glycol or glycerol), nicotine (in most cases), and fl avourings (in many cases), to deliver an aerosol that is inhaled by the user. E-cigarette use is increasing in many countries. 1, 2 Adults report various motivations for e-cigarette use, including to help them quit cigarettes and allowing them to continue to use nicotine in areas where smoking is prohibited, [3] [4] [5] [6] [7] which are common themes in e-cigarette marketing and promotion. [8] [9] [10] In 2015, the US Preventive Services Task Force concluded that evidence was insuffi cient to recommend e-cigarettes for tobacco cessation in adults because of confl icting and limited evidence available at the time the recommendation was prepared. 11 Two meta-analyses of combined results from clinical trials have assessed whether e-cigarette use is associated with smoking cessation. 12, 13 The fi rst, 12 based on two randomised trials, 14, 15 concluded that participants using nicotine e-cigarettes were more likely to have abstained from smoking cigarettes for 6 months (relative risk 2·29, 95% CI 1·05-4·96) than were participants using nonicotine e-cigarettes, although the authors had little confi dence in the results because of the small number of trials and small sample sizes. The second, 13 based on six studies (the same two randomised trials, 14, 15 two cohort studies, 16, 17 and two cross-sectional studies 18, 19 ) found the proportion of individuals using nicotine-containing e-cigarettes who quit cigarettes to be 20% (95% CI [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . These meta-analyses did not compare e-cigarette users to a control group not using e-cigarettes. A third metaanalysis 20 of fi ve population-level studies (four longitudinal [21] [22] [23] [24] and one cross-sectional 25 ) found that e-cigarette use was associated with a signifi cant depression in smoking cessation (odds ratio [OR] 0·61, 95% CI 0·50-0·75).
The diff erent results of the meta-analyses of clinical trials and observational studies may relate to discrepancies in how e-cigarettes are used in a controlled study setting versus in the real world. Clinical trials evaluating a treatment or intervention under ideal conditions may diff er from observational studies evaluating how a product is actually used in a real-world setting in study design, study population, study environment, 26 and ability to control for potential confounders, which can compromise the generalisability of results of observational studies. 27 These diff erences are potentially important for e-cigarettes, which, unlike prescription-only nicotine inhalers, are mass-marketed consumer products. We conducted a systematic review and meta-analysis of clinical trials and observational real-world studies to assess the association between e-cigarettes (as available and used) and cigarette smoking cessation among adults, including all smokers as well as only those interested in quitting smoking.
Methods

Data sources and searches
To identify studies, we began by manually searching the references from the three earlier meta-analyses 12, 13, 20 and completed a comprehensive literature search of PubMed and the Web of Science Core Collection between April 27, 2015, and June 17, 2015. As detailed in the appendix, search terms included "electronic cigarette", "e-cigarette", "electronic nicotine delivery", "stop", "quit", "cessation", "abstain", and "abstinence". Search results were not limited by language, but all identifi ed studies were in English. There was no search limitation on publication dates. We continued to monitor the scientifi c literature after completing the formal search; this report includes two studies that were published while it was in initial peer review. 28, 29 Both abstracts and full manuscripts were considered.
Study selection
One investigator (SK) did the search, data extraction, and risk of bias assessment, which was subsequently reviewed by a second investigator (SAG). Clinical trials, whether randomised and controlled or not, cohort studies, and cross-sectional studies were all considered. We included studies that evaluated the relationship between e-cigarette use and cigarette smoking cessation among adult cigarette smokers; therefore, two studies on adolescents were excluded. 30, 31 We considered all study populations that were defi ned as "adult" by the study authors (youngest age varied from 15 to 30 years in the studies that defi ned "adult"; detailed descriptions of each article are provided in the appendix). We included studies of participants who were interested in quitting cigarette smoking and studies of all smokers irrespective of interest in quitting. We excluded one cross-sectional study 25 because the primary outcome was e-cigarette use, not smoking cessation.
Data extraction
Studies that included cigarette smoking cessation as a primary outcome were evaluated for inclusion. The defi nitions of cigarette smoking cessation included in this systematic review and meta-analysis included both self-reported abstinence from smoking cigarettes and biochemically-validated measures of abstinence (eg, cotinine or exhaled carbon monoxide measurements). All studies were included irrespective of the duration of abstinence from cigarettes. Those who quit cigarettes could have still been using e-cigarettes; quitting e-cigarettes was not used as an outcome.
Data extracted from each study included study location, design, population, defi nition and prevalence of e-cigarette use, comparison group (if applicable),
Panel: Research in context
Evidence before this study We searched PubMed and Web of Science between April 27, 2015, and June 17, 2015, for articles that evaluated the association between e-cigarette use and cigarette smoking cessation among adult cigarette smokers. All relevant papers were included, irrespective of where the research was conducted or quality of the studies. There were no language restrictions, although all the papers were written in English. We included two additional studies published while this report was under peer review. Two earlier meta-analyses, one based on two randomised trials, and another based on six studies (the same two randomised trials plus two cohort studies and two cross-sectional studies), suggested that e-cigarettes might assist smokers in quitting cigarettes. These meta-analyses did not compare e-cigarette users to a control group not using e-cigarettes. The fi rst meta-analysis (of two randomised trials) concluded that participants using nicotine e-cigarettes were more likely to have abstained from smoking cigarettes for at least 6 months (relative risk 2·29, 95% CI 1·05-4·96) than were participants using no-nicotine e-cigarettes. The second meta-analysis concluded that the proportion of individuals using nicotine-containing e-cigarettes who quit cigarettes to be 20% (95% CI [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . A third meta-analysis of fi ve population-level observational studies found that e-cigarette use was associated with a signifi cant depression in smoking cessation.
Added value of this study
We include all available (38) studies in our systematic review and all 20 studies with control groups (15 cohort studies, three cross-sectional studies, and two clinical trials) in our metaanalysis. Odds of quitting cigarettes were 28% lower in those who used e-cigarettes compared with those who did not use e-cigarettes (odds ratio 0·72, 95% CI 0·57-0·91). Sensitivity analysis showed that the results were not aff ected by a wide range of study design factors.
Implications of all the available evidence
As currently being used, e-cigarettes are associated with signifi cantly less quitting among smokers. According to the results of our systematic review and meta-analysis, e-cigarettes should not be recommended as eff ective smoking cessation aids until there is evidence that, as promoted and used, they assist smoking cessation. 
Data synthesis
For studies comparing nicotine e-cigarettes with nicotine replacement therapy (NRT), no-nicotine e-cigarettes, or no cessation aid, all ORs are presented; when several ORs were provided, we included only the comparison with no e-cigarette use (when available) or no cessation aid in the meta-analysis. Adjusted ORs were used when available, otherwise unadjusted ORs were used. For one cohort study, 7 two diff erent ORs were reported for e-cigarette users of diff erent intensities and a pooled estimate was not provided; the ORs for those two groups are presented separately.
Statistical analysis
We computed pooled estimates of the odds of smoking cessation among smokers using e-cigarettes compared with smokers not using e-cigarettes using a random eff ects meta-analysis with the metan command in Stata version 13.0. Adjusted ORs were used when available, with unadjusted ORs for the remaining studies in the meta-analysis. Statistical heterogeneity was assessed using the I² statistic.
We did a sensitivity analysis of the eff ects of study type (real world vs clinical), longitudinal versus crosssectional data analysis, sample frame (smokers interested in quitting vs all smokers), control group (NRT users vs all no-e-cigarette users), study population (mental illness or no mental illness), whether the study controlled for level of nicotine dependence, time of e-cigarette assessment (whether e-cigarette use was assessed at baseline or follow-up in longitudinal studies), whether abstinence was biochemically defi ned, and whether the defi nition of e-cigarette use was current (past 30 day) use versus ever-use or not within the past 30 days on the results using separate random eff ects meta-regressions with each factor entered as a dummy variable with the Stata metareg command. We considered the nine sensitivity analyses to be a family of comparisons and controlled for multiple comparisons using the Holm-Sidak method to obtain adjusted p values. We tested for the presence of publication bias using a funnel plot and Egger's test.
The meta-analysis was registered with PROSPERO on May 11, 2015, number CRD42015020382.
Role of the funding source
The funders had no role in the study design, collection, analysis, or interpretation of the data, or writing of the report. Both authors had access to the raw data. Both authors had full access to all of the data the study and had fi nal responsibility for the decision to submit for publication.
Results
Of 577 studies identifi ed, 38 were included in the systematic review (appendix) and 20 (table 1) in the metaanalysis. Studies excluded from the systematic review did not include smoking cessation as an outcome, did not include adults as the study population, were opinion pieces or commentaries, or were review articles (fi gure 1). Of the 38 studies included in the systematic review, 16 were excluded from the meta-analysis because they lacked a control group that did not use e-cigarettes, [15] [16] [17] 19, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] and two 57, 58 were excluded because they used the same dataset as another study included in the meta-analysis. 14, 38 15 of the studies included in the meta-analysis were longitudinal cohort studies (ten assessed e-cigarette use at baseline, fi ve assessed e-cigarette use only at followup), three were cross-sectional studies, and two were clinical trials. 10 full-texts excluded 7 outcome not smoking cessation or abstinence 1 lack of specific numbers on cessation or abstinence 1 abstract of included study 1 case series 18 excluded from meta-analysis:
16 study lacking control group 2 used same dataset as another study from meta-analysis
Odds of quitting (only provided for studies with a control group) are described with point estimates and 95% CIs and whether these point estimates diff ered signifi cantly from 1·00.
15 longitudinal real-world studies assessing smoking cessation in e-cigarette users compared with those who did not use e-cigarettes.
7,21-24,34-43 Point estimates in 13 of the 15 studies indicated decreased smoking cessation among those who used e-cigarettes, six of which reported statistically signifi cant results. 24, 34, 36, 40, 41, 43 One study 7 found that intensive e-cigarette users (those who used e-cigarettes daily for at least 1 month) had signifi cantly increased smoking cessation and that intermittent e-cigarette users had a non-signifi cant decrease in smoking cessation. In three studies without control groups (excluded from the meta-analysis), 16, 45, 46 smoking cessation rates among e-cigarette users ranged from 17% at 8 weeks, 45 to 41% at 1 year, 46 to 46% at 1 year. 16 Three cross-sectional studies compared e-cigarette users to those who did not use e-cigarettes:
18,28,44 two 28, 44 showed signifi cantly lower smoking cessation among smokers using e-cigarettes compared with those who did not, and the other study 18 (of smokers who had made a quit attempt in the past year) found signifi cantly higher smoking cessation in those who used e-cigarettes compared with those who used NRT or no smoking cessation aid. Cigarette quit rates in cross-sectional studies that included only e-cigarette users (ie, studies without control groups, which were excluded from the meta-analysis) ranged from 10% to 66%. 19, [47] [48] [49] The one randomised controlled trial comparing cigarette quit rates of e-cigarette users with those of NRT users showed a non-signifi cant increase in quitting associated with e-cigarette use.
14 A secondary analysis of a subset of participants with mental illness in this study showed a non-signifi cant decrease in quitting among those who used e-cigarettes compared with those who used NRT. 58 A non-randomised clinical trial found a non-signifi cant increase in quitting among individuals electing to use e-cigarettes for smoking cessation compared with those not using e-cigarettes. 
Longitudinal
Adkison (2013) 23 Bullen (2013), clinical trial 14 Vickerman (2013) 24 Borderud (2014) 34 Choi (2014) 21 Grana (2014) 22 Pearson (2015) 42 Prochaska (2014) 35 Al-Delaimy (2015) 36 Biener (2015), intense 7 Biener (2015), intermittent 7 Hajek (2015), clinical trial 29 Harrington (2015) 37 Hitchman (2015) 38 Manzoli (2015) 39 Pavlov (2015) 40 Shi (2015) 43 Sutfin (2015) 41 Subtotal (I 2 61·5%, p<0·0005)
Cross-sectional
Brown (2014) 18 Christensen (2014) 44 McQueen (2015) For trials without control groups 17, [50] [51] [52] [53] [54] [55] [56] (ie, all participants used e-cigarettes), cigarette quit rates ranged from 12·5% to more than 40%. A randomised trial comparing users of e-cigarettes with and without nicotine (without a control group of non-e-cigarette users or conventional smoking cessation therapy) found a non-signifi cant increase in quitting cigarettes for those using nicotinecontaining e-cigarettes compared with those using nonnicotine e-cigarettes. 15 Combining the 18 real-world studies 7, 18, [21] [22] [23] [24] 28, [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] (treating one study 7 with estimates for two types of e-cigarette users as two studies, yielded 19 real-world estimates of the relationship between e-cigarette use and quitting smoking) and the two clinical trials 14, 29 in a random eff ects meta-analysis (fi gures 2, 3) indicated that the odds of quitting smoking were 28% lower in those who used e-cigarettes compared with those who did not use e-cigarettes (OR 0·72, 95% CI 0·57-0·91).
Studies that included only smokers interested in quitting cigarettes yielded a pooled OR for quitting of 0·86 (0·60-1·23) for those using e-cigarettes compared with those not using e-cigarettes. Studies of all smokers (irrespective of motivation to quit) yielded a pooled OR of 0·63 (0·45-0·86), which is not signifi cantly diff erent from studies limited to smokers interested in quitting (p=0·94).
All of the observational studies had low risk of selection bias, half (nine of 18) controlled for confounders, and seven of 15 longitudinal studies had follow-up periods of at least 6 months (appendix). The overall risk of bias from exposure measurement was unclear, given that the defi nition of e-cigarette use in all but two 7, 39 of the studies could have included people who only used e-cigarettes once; risk of bias from outcome assessment was unclear or high due to objective or poorly defi ned measurements.
The one randomised clinical trial 14 had a low risk of selection, detection, and reporting bias, but a high risk of performance and attrition bias, because participants randomly assigned to e-cigarettes were provided with the e-cigarettes, whereas the individuals randomly assigned to nicotine patches were provided a voucher that they 
All smokers
Adkison (2013) 23 Choi (2014) 21 Christensen (2014) 44 Grana (2014) 22 Prochaska (2014) 35 Al-Delaimy (2015) 36 Biener (2015), intense 7 Biener (2015), intermittent 7 Harrington (2015) 37 Hitchman (2015) 38 Manzoli (2015) 39 McQueen (2015) 28 Shi (2015) 43 Sutfin (2015) 41 Subtotal (I 2 63·3%, p=0·0001)
Smokers interested in quitting
Bullen (2013), clinical trial 14 Vickerman (2013) 24 Borderud (2014) 34 Brown (2014) 18 Hajek (2015), clinical trial 29 Pavlov (2015) 40 Pearson (2015) 42 Subtotal (I 2 88·3%, p<0·0005) Overall (I 2 77·4%, p<0·0005) could take to a pharmacy to obtain the patches; additionally, the nicotine patch group had a higher loss to follow-up than did the e-cigarette group (appendix). The non-randomised controlled trial 29 had low risk of detection, attrition, and reporting bias, but high risk of selection and performance bias because participants were not randomised and had chosen to use e-cigarettes.
0·72 (0·57-0·91)
4·80%
We did not fi nd evidence of publication bias by Egger's test (p=0·91) or by visualisation of the funnel plot (appendix).
There was evidence of heterogeneity of the studies (I² 77·4%, p<0·0005). In particular, heterogeneity was higher for the cross-sectional studies (I² 94·4%, p<0·0005) than the longitudinal studies (I² 61·5%, p<0·0005). In addition to using a random eff ects model to control for heterogeneity, we assessed the possible reasons for heterogeneity in a sensitivity analysis (table 2). In the sensitivity analyses, sample frame, study type (longitudinal vs cross-sectional data analysis), control group, study population, level of nicotine dependence, time of e-cigarette assessment (in longitudinal studies), biochemical verifi cation of smoking cessation, and defi nition of e-cigarette use were not associated with overall eff ect size (p≥0·77 in all cases).
Discussion
In this systematic review and meta-analysis, pooled results from 18 real-world observational studies and two clinical trials showed 28% (OR 0·72, 95% CI 0·57-0·91) lower odds of cigarette smoking cessation among those who used or had used e-cigarettes compared with those who had not used e-cigarettes. This conclusion was insensitive to a wide range of study design factors, including whether or not the study population consisted only of smokers interested in smoking cessation, or all smokers (irrespective of quit intention).
The results of this meta-analysis are consistent with those of the previous meta-analysis of fi ve real-world studies, 20 which found a pooled OR for quitting of 0·61 (95% CI 0·50-0·75) for those who used e-cigarettes compared with those who did not use e-cigarettes.
By contrast, two previous meta-analyses, 12,13 which both included the same two clinical trials to compare nicotine e-cigarette users with non-nicotine e-cigarette users, 14, 15 showed the odds of quitting cigarettes to be twice as high in those using e-cigarettes with nicotine compared with those using e-cigarette without nicotine (2·29, 95% CI 1·05-4·96). 12 One of the previous meta-analyses, 13 based on six studies, found that 20% (95% CI 11-28) of users of nicotine-containing e-cigarettes went on to quit cigarettes. By contrast with our analysis, the estimates did not include a comparison to standard therapy or no e-cigarette use, so they cannot be used to determine whether e-cigarettes are associated with greater cigarette abstinence than current practice.
So far, no clinical trials have done a true head-to-head comparison of e-cigarettes with standard therapies (ie, nicotine patch, gum, or inhaler) approved by the US Food and Drug Administration for smoking cessation. The one randomised clinical trial included in this metaanalysis 14 compared e-cigarettes with nicotine patches, but was subject to performance bias because individuals randomly assigned to e-cigarettes were provided with them by the investigators, whereas participants randomly assigned to NRT were given only a voucher that they could redeem at a pharmacy to obtain NRT patches. Although this practice is consistent with standard care in the country in which the study was done (New Zealand), it potentially biases the study against NRT. As a result, true head-to-head comparisons of e-cigarettes with approved therapies in a clinical setting are needed to evaluate the usefulness of e-cigarettes for smoking cessation. In the USA, such studies require Investigational New Drug approval from the Food and Drug Administration Center for Drug Evaluation and Research. If e-cigarette companies do not request this approval (as has been the case to date), such studies will be diffi cult, if not impossible, to conduct, unless at the request of the companies. Heterogeneity was higher for the cross-sectional studies (I² 94·4%, p<0·0005) than the longitudinal studies (I² 61·5%, p<0·0005). This increased heterogeneity might result from the fact that there were only three cross-sectional studies (compared with 18 longitudinal estimates), and that they diff ered in terms of countries (one in the UK 18 and two in the USA 28, 44 ), study population (two only of smokers interested in quitting, 18, 28 one of all smokers 44 ), comparator group (one compared e-cigarettes with NRT 18 and the other two compared with no e-cigarette use 28, 44 ) , and adjustment for nicotine dependence (one 18 was adjusted, two 28, 44 were not). There was no evidence of study type (longitudinal vs cross-sectional) being associated with the overall eff ect size.
There could be a number of explanations for why e-cigarette use was associated with less quitting in this meta-analysis combining observational and clinical studies. When considering e-cigarettes as a potential smoking cessation aid, the fact that they are freely available consumer products could be important. The situation may be similar to the diff erences between the clinical effi cacy of approved NRT therapies for smoking cessation in clinical trials versus actual use in nonclinical settings. A few studies have evaluated the association of other forms of over-the-counter nicotine with smoking cessation. Data from the large populationbased California Tobacco Surveys, showed that NRT was associated with long-term success in quitting cigarettes when available by prescription only, but this association was lost when NRT became available over the counter. 59 In a prospective cohort study of adult smokers in England, prescription medication combined with behavioural counselling was associated with increased smoking cessation, whereas over-the-counter NRT was associated with a signifi cant reduction in smoking cessation (OR 0·68, 95% CI 0·49-0·94) that was similar to the association between e-cigarette use and quitting smoking that we observed. 60 In observational studies evaluating e-cigarette use, participants are choosing to use e-cigarettes unlike clinical trials where they are being randomly assigned to receive them. From one perspective, this self-selection of product use by individuals would be a potential source of selection bias 61 when evaluating e-cigarettes as a smoking cessation aid. However e-cigarettes are not being used just as smoking cessation devices in the real world. Indeed, one important motivation for using e-cigarettes is to self-administer nicotine in places where smoking is prohibited. 3, 62 Interest in quitting cigarette smoking is a common reason for using e-cigarettes, 3, 4 probably because claims of effi cacy as a cessation aid have appeared in e-cigarette advertisements in the USA, 9 UK, 8 and China 10 even though such claims had not been accepted by regulatory authorities. E-cigarettes are also marketed as a way to circumvent smoke-free policies, 8, 9 and could be used as such by nicotine-dependent individuals who have lower baseline intentions of quitting. Subgroup analyses in two of the studies suggest that specifi c use patterns may be important. Biener and colleagues 7 found that intermittent e-cigarette users (more than once or twice but less than daily use) were less likely to quit smoking one year later than non-ecigarette users, but those who had used e-cigarettes daily for at least one month were signifi cantly more likely to quit cigarettes. Similarly, Hitchman and colleagues 38 found that all "cig-alike" users and non-daily tank system users had lower odds of quitting cigarettes, whereas daily tank system users were signifi cantly more likely to quit. By contrast, Manzoli and colleagues 39 found a nonsignifi cant (OR 0·83, 95% CI 0·53-1·29) reduction in quitting cigarettes among cigarette smokers who regularly used e-cigarettes (defi ned as using both cigarettes and e-cigarettes within the same week for 6 months) compared with cigarette-only smokers. These data suggest that e-cigarette use patterns might be important in the association between e-cigarettes and smoking cessation.
E-cigarette regulation has the potential to infl uence marketing and reasons for use. The inclusion of e-cigarettes in smoke-free laws and voluntary smokefree policies could help decrease use of e-cigarettes as a cigarette substitute and, perhaps, increase their eff ectiveness for smoking cessation. The way e-cigarettes are available on the market-for use by anyone and for any purpose-creates a disconnect between the provision of e-cigarettes for cessation as part of a monitored clinical trial and the availability of e-cigarettes for use by the general population. Therefore, careful attention to how the products are marketed and actually used will be necessary in evaluating e-cigarettes as a smoking cessation aid and their ultimate public health impact. 63 The studies we reviewed controlled for many confounding variables, including level of nicotine dependence, whether the subject was trying to quit smoking cigarettes, demographics, past quit attempts, medical and psychiatric comorbidities, cigarette consumption, intention or motivation to quit, study factors, tobacco-related variables and behaviours, alcohol use, sensation seeking, number of friends and family who smoke, use of other quit methods, and type of tobacco smoked (table 1) . Future research should focus on determining standard defi nitions of e-cigarette use; evaluating the association of diff erent extents of use and diff erent devices with smoking cessation; conducting more randomised clinical trials comparing e-cigarettes to standard therapies such as NRT; evaluating the eff ect of e-cigarette use on factors such as motivation to quit; and distinguishing e-cigarette users by their reasons for using the products. An ideal study (whether a clinical trial or observational study) would control for all these variables, and be a longitudinal study that assessed e-cigarette use at both the start and end, including product type used and frequency of use. Additionally, having clear defi nitions of e-cigarette use (ever use, past 30 day use, whether experimentation with e-cigarettes once or twice are included) is important, as is how cessation is defi ned. It will, unfortunately, likely be diffi cult to obtain all these details in any one study.
This study is subject to eight limitations. First, given that there have been very few controlled clinical trials exploring e-cigarette use for smoking cessation; all but two of the studies used in this meta-analysis were observational studies. Second, the defi nition of smoking cessation used in the studies included in the metaanalysis varied in terms of length of abstinence from cigarettes and how smoking cessation was defi ned. Because we aimed for a comprehensive review, we included all defi nitions of quit as defi ned by the authors. Third, most-but not all-of the observational studies controlled for confounders such as nicotine dependence. Sensitivity analysis showed that controlling for nicotine dependence was not associated with overall eff ect size. Other potential confounding variables were controlled for in some of the studies, however, sensitivity analyses could not be conducted on each of these variables. Nevertheless, it is always possible that other unidentifi ed confounders, including biases introduced by those who self-selected to use e-cigarettes, might aff ect the results. Fourth, only two studies 7, 39 assessed the extent of e-cigarette use in their analyses. It is possible that in some included studies, e-cigarettes were only used once, which would not be a good predictor of smoking cessation. Fifth, there was variability in the quality of the studies. We included them all to provide a comprehensive review of the literature and avoid concerns that the results of the analysis were aff ected by bias in selecting which studies to exclude and include. The sensitivity analysis showed that the results of the meta-analysis were insensitive to a wide range of aspects of study design. Sixth, in the cross-sectional studies, e-cigarette use and cessation were assessed at the same time, raising concerns about recall bias. Seventh, e-cigarettes are rapidly evolving products and diff erent types and generations of e-cigarettes may have diff erent eff ects in terms of cessation. Finally, both e-cigarette products and the marketing and regulatory environment are rapidly evolving, all of which could aff ect the relationship between e-cigarette use and quitting smoking.
As use patterns and product types continue to evolve, the association between e-cigarettes and cigarette quit rates may change. In the current regulatory environment, e-cigarette use is increasing and, although quitting smoking is a common marketing claim and is often cited as a reason for use among cigarette smokers, the overall conclusion from the available studies is that e-cigarette use is associated with reduced smoking cessation in the real world.
